Working… Menu

Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01107067
Recruitment Status : Completed
First Posted : April 20, 2010
Last Update Posted : April 20, 2010
Information provided by:
Gulhane School of Medicine

Brief Summary:
The purpose of this study is investigating the effect of testosterone treatment on paraoxonase level in male patients with hypogonadotrophic hypogonadism

Condition or disease Intervention/treatment Phase
Hypogonadism Drug: Sustanon Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Phase IV Study to Investigate the Effect of Testosterone Treatment on Paraoxonase Level in Male Patients With Hypogonadotrophic Hypogonadism
Study Start Date : June 2008
Actual Primary Completion Date : December 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: testosterone replacement therapy Drug: Sustanon
250 mg/21 days
Other Name: no name

Primary Outcome Measures :
  1. paraoxonase level after testosterone treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 25 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Volunteers patients with hypogonadism

Exclusion Criteria:

  • Coronary heart disease
  • Other pituitary/hypothalamic disorders or other non-hypogonadism diseases
  • None was receiving vitamins, lipid-lowering drugs, or other medications known to interfere with PON1 activity, lipid profile, or gonadal function

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01107067

Layout table for location information
Ankara, Turkey, 06600
Sponsors and Collaborators
Gulhane School of Medicine

Layout table for additonal information
Responsible Party: Gulhane School of Medicine Department of Endocrinology and Metabolism Identifier: NCT01107067     History of Changes
Other Study ID Numbers: aa001
First Posted: April 20, 2010    Key Record Dates
Last Update Posted: April 20, 2010
Last Verified: May 2008
Keywords provided by Gulhane School of Medicine:
Additional relevant MeSH terms:
Layout table for MeSH terms
Gonadal Disorders
Endocrine System Diseases
Testosterone undecanoate
Testosterone enanthate
Testosterone 17 beta-cypionate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents